Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Voyager Therapeutics has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2024.
Voyager Therapeutics's investors include Wellington Management, Third Rock Ventures, Fidelity, Deerfield, Casdin Capital.
Voyager Therapeutics is headquartered in Cambridge, United States.
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Voyager Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Voyager Therapeutics — Funding & Investors." VCBacked, January 4, 2024, https://www.vcbacked.co/company/voyager-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). Voyager Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/voyager-therapeutics
{{cite web |title=Voyager Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/voyager-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated